Repurposed agents in the Alzheimer’s disease drug development pipeline

Repurposed agents in the Alzheimer’s disease drug development pipeline

Abstract Background Treatments are needed to address the growing prevalence of Alzheimer’s disease (AD). Clinical trials have failed to produce any AD drugs for Food and Drug Administration (FDA) approval since 2003, and the pharmaceutical development process is both time-consuming and costly. Drug...

Full description

Bibliographic Details
Main Authors: Justin Bauzon, Garam Lee, Jeffrey Cummings
Format: Article
Language:English
Published: BMC 2020-08-01
Series:Alzheimer’s Research & Therapy
Subjects:
Alzheimer’s disease
Clinical trials
Repurposing
Dose
Formulation
Disease-modification
Online Access:http://link.springer.com/article/10.1186/s13195-020-00662-x

Internet

http://link.springer.com/article/10.1186/s13195-020-00662-x

Similar Items